A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.
[1] VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include: Phase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4] Phase III : DMXAA (ASA404).
This antineoplastic or immunomodulatory drug article is a stub.
You can help Wikipedia by expanding it.